GLOBAL BLOOD THERAPEUTICS Stock News

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin™ gene therapy for ad

Forma Therapeutics has filed to raise $150 million in an IPO, although the final figure may differ. The firm is developing treatments for sickle cell disease an

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

Shares in Global Blood Therapeutics (GBT) rose 5% in Monday’s extended trading after the company announced plans to expand the potential use of Oxbryta (voxelotor) for the treatment of sickle cell

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Biohaven Pharmaceutical...

Read more about Health News Roundup: WHO head urges world not to drop guard; Over half of people tested in Italian city of Bergamo and more on Devdiscourse

Oxbryta is the first and only therapy that directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. It is currently approved in the Unite

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SOUTH SAN FRANCISCO, Calif., June 03, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2020, the compensation committee of GBT’s.

Q1 2020 Global Blood Therapeutics Inc Earnings Call

SOUTH SAN FRANCISCO, Calif., June 02, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Goldman Sachs 41st Annual Global.

Here's why it is now a great opportunity to buy a company making an innovative therapy for patients with sickle cell disease.

The

Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quar